Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 13;18(1):41.
doi: 10.1186/s13012-023-01297-w.

Implementing contingency management for stimulant use in opioid treatment programs: protocol of a type III hybrid effectiveness-stepped-wedge trial

Sara J Becker  1 , Kira DiClemente-Bosco  2 , Kelli Scott  2 , Tim Janssen  3 , Sarah M Salino  2 , Fariha N Hasan  2 , Kimberly R Yap  2 , Bryan R Garner  4
Affiliations

Implementing contingency management for stimulant use in opioid treatment programs: protocol of a type III hybrid effectiveness-stepped-wedge trial

Sara J Becker et al. Implement Sci. .

Abstract

Background: Contingency management (CM) is an evidence-based intervention for stimulant use and is highly effective in combination with medication for opioid use disorder. Yet, uptake of CM in opioid treatment programs that provide medication for opioid use disorder remains low. This paradox in which CM is one of the most effective interventions, yet one of the least available, represents one of the greatest research-to-practice gaps in the addiction health services field. Multi-level implementation strategies are needed to address barriers to CM implementation at both the provider- and organization-level. This type III hybrid effectiveness-implementation trial was funded by the National Institute on Drug Abuse to evaluate whether a multi-level implementation strategy, the Science of Service Laboratory (SSL), can effectively promote CM implementation in opioid treatment programs. Specific aims will test the effectiveness of the SSL on implementation outcomes (primary aim) and patient outcomes (secondary aim), as well as test putative mediators of implementation outcomes (exploratory aim).

Methods: Utilizing a fully powered type III hybrid effectiveness-implementation trial with a stepped wedge design, we propose to randomize a cohort of 10 opioid treatment programs to receive the SSL across four steps. Each step, an additional 2-3 opioid treatment programs will receive the SSL implementation strategy, which has three core components: didactic training, performance feedback, and external facilitation. At six intervals, each of the 10 opioid treatment programs will provide de-identified electronic medical record data from all available patient charts on CM delivery and patient outcomes. Staff from each opioid treatment program will provide feedback on contextual determinants influencing implementation at three timepoints.

Discussion: Between planning of this protocol and receipt of funding, the landscape for CM in the USA changed dramatically, with multiple Departments of Health launching state-wide CM initiatives. We therefore accelerated the protocol timeline and offered some cursory training resources to all sites as a preparation activity. We also began partnering with multiple Departments of Health to evaluate their rollout of CM using the measures outlined in this protocol.

Trial registration: This study protocol is registered via ClinicalTrials.gov Identifier: NCT05702021. Date of registration: January 27, 2023.

Keywords: Hybrid effectiveness-implementation; Implementation; Stepped wedge trial; Substance use disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Stepped wedge design and timeline. Ten opioid treatment programs are randomized to crossover from usual care (depicted in grey) to receipt of the Science to Service Laboratory across four wedges. The Science to Service Laboratory consists of preparation activities (depicted in blue) and active implementation activities (depicted in yellow). Following 6 months of active Science to Service Laboratory support, the programs shift into a sustainment phase (depicted in green) during which they receive minimal support. Programs provide data at the 0, 6, 12-, 18-, 24-, and 30-month marks
Fig. 2
Fig. 2
Elements of the Science to Service Laboratory
See this image and copyright information in PMC

References

    1. Bolivar HA, Klemperer EM, Coleman SRM, DeSarno M, Skelly JM, Higgins ST. Contingency management for patients receiving medication for opioid use disorder: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(10):1092–1102. - PMC - PubMed
    1. Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000;58(1–2):55–66. - PubMed
    1. Resnick RB, Galanter M, Pycha C, Cohen A, Grandison P, Flood N. Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol Bull. 1992;28(1):109–113. - PubMed
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009(3):CD002209. 10.1002/14651858.CD002209.pub2. Accessed 4 Sept 2023. - PMC - PubMed
    1. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–1513. - PubMed

Publication types

Substances

Associated data